NASDAQ:APVO Aptevo Therapeutics (APVO) Stock Price, News & Analysis $0.45 -0.02 (-3.25%) Closing price 04:00 PM EasternExtended Trading$0.45 +0.01 (+1.12%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsSEC Filings About Aptevo Therapeutics Stock (NASDAQ:APVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aptevo Therapeutics alerts:Sign Up Key Stats Today's Range$0.42▼$0.4750-Day Range$0.45▼$1.9152-Week Range$0.42▼$25.56Volume630,792 shsAverage Volume101,091 shsMarket Capitalization$807.26 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Aptevo Therapeutics is a biotechnology company focused on developing immunotherapies, particularly treatments for cancer. Its research uses engineered antibody-based approaches intended to direct or activate the immune system against disease. The company’s programs have included APVO436, a bispecific antibody designed to connect CD3-positive T cells with CD123-positive leukemia cells and investigated as a potential treatment for acute myeloid leukemia. Aptevo has also worked on other immune-targeting candidates, including programs designed to stimulate immune responses against tumors. Aptevo was established in 2016 as a spin-off from Emergent BioSolutions. The company is based in Seattle, Washington, and its work is centered on research and development rather than a broad portfolio of marketed medicines.AI Generated. May Contain Errors. Read More Aptevo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreAPVO MarketRank™: 1.014512410145 of 5 starsAptevo Therapeutics scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingAptevo Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAptevo Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Aptevo Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aptevo Therapeutics are expected to grow in the coming year, from ($17.04) to ($6.59) per share.Price to Book Value per Share RatioAptevo Therapeutics has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.95% of the float of Aptevo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAptevo Therapeutics has a short interest ratio ("days to cover") of 1.93, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptevo Therapeutics has recently decreased by 26.18%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAptevo Therapeutics does not currently pay a dividend.Dividend GrowthAptevo Therapeutics does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment-0.54 News SentimentAptevo Therapeutics has a news sentiment score of -0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Aptevo Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Aptevo Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.37% of the stock of Aptevo Therapeutics is held by insiders.Percentage Held by Institutions8.06% of the stock of Aptevo Therapeutics is held by institutions.Read more about Aptevo Therapeutics' insider trading history. Receive APVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APVO Stock News HeadlinesAptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial ResultsNovember 16 at 10:47 AM | finance.yahoo.comAptevo Reports 79% Remission Rate in TP53-Mutated AMLNovember 16 at 8:51 AM | quiverquant.comQ$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.November 18 at 1:00 AM | Profits Run (Ad)Aptevo Therapeutics Announces Warrant Exercise Financing AgreementNovember 12, 2026 | tipranks.comAptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross ProceedsNovember 12, 2026 | finanznachrichten.deAptevo Therapeutics announces exercise of existing warrants for $3M gross proceedsNovember 11, 2026 | msn.comAptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross ProceedsNovember 11, 2026 | finance.yahoo.comAptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid TumorsNovember 9, 2026 | finance.yahoo.comSee More Headlines APVO Stock Analysis - Frequently Asked Questions How have APVO shares performed this year? Aptevo Therapeutics' stock was trading at $9.43 at the beginning of the year. Since then, APVO stock has decreased by 95.3% and is now trading at $0.4460. How were Aptevo Therapeutics' earnings last quarter? Aptevo Therapeutics Inc. (NASDAQ:APVO) announced its quarterly earnings results on Monday, November, 16th. The biotechnology company reported ($5.19) earnings per share for the quarter, missing the consensus estimate of ($3.71) by $1.48. When did Aptevo Therapeutics' stock split? Aptevo Therapeutics shares reverse split before market open on Wednesday, March 6th 2024.The 1-44 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, March 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Aptevo Therapeutics? Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aptevo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), Canopy Growth (CGC), Micron Technology (MU), Inovio Pharmaceuticals (INO) and Intel (INTC). Company Calendar Last Earnings11/16/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (65m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 APVO's financial health is in the Red zone, according to TradeSmith. APVO has been in this zone for over 65 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:APVO CIK1671584 Webwww.aptevotherapeutics.com Phone(206) 838-0500Fax206-838-0503Employees33Year Founded2016Profitability EPS (Trailing Twelve Months)($51.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-217.57% Return on Assets-123.71% Debt Debt-to-Equity RatioN/A Current Ratio2.08 Quick Ratio2.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$17.42 per share Price / Book0.03Miscellaneous Outstanding Shares1,810,000Free Float1,803,000Market Cap$807.26 thousand OptionableNot Optionable Beta1.65 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:APVO) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.